Denileukin Difitox (Ontak) For The Treatment Of Advanced Steroid-Refractory GVHD: Single Institution Experience

MLA

Abar, F., et al. “Denileukin Difitox (Ontak) For The Treatment Of Advanced Steroid-Refractory GVHD: Single Institution Experience.” Biology of Blood & Marrow Transplantation, vol. 15, Feb. 2009, pp. 129–30. EBSCOhost, https://doi.org/10.1016/j.bbmt.2008.12.396.

APA

Abar, F., Leis, J. F., Jacoby, C. E., Mishra, M., Bubalo, J. S., Curtin, P. T., Hayes-Lattin, B. L., Meyers, G., Slater, S. E., Subbiah, N., & Maziarz, R. T. (2009). Denileukin Difitox (Ontak) For The Treatment Of Advanced Steroid-Refractory GVHD: Single Institution Experience. Biology of Blood & Marrow Transplantation, 15, 129–130. https://doi.org/10.1016/j.bbmt.2008.12.396

Chicago

Abar, F., J.F. Leis, C.E. Jacoby, M. Mishra, J.S. Bubalo, P.T. Curtin, B.L. Hayes-Lattin, et al. 2009. “Denileukin Difitox (Ontak) For The Treatment Of Advanced Steroid-Refractory GVHD: Single Institution Experience.” Biology of Blood & Marrow Transplantation 15 (February): 129–30. doi:10.1016/j.bbmt.2008.12.396.